Evidence map›Paper›PMID 40544202›Full record

ReviewMolecular biology reports2025

Mechanistic insight into nanomedicine for polycystic ovary syndrome.

Maisra Azhar Butt, Sobia Tabassum, Rowan S Hardy, Mubin Mustafa Kiyani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maisra Azhar ButtDepartment of Biological Sciences, Faculty of Sciences, International Islamic University, Islamabad, Pakistan.
Sobia TabassumDepartment of Biological Sciences, Faculty of Sciences, International Islamic University, Islamabad, Pakistan. sobia.tabasum@iiu.edu.pk.
Rowan S HardyDepartment of Biomedical Sciences, School of Infection, Inflammation & Immunology, The University of Birmingham, Birmingham, UK.
Mubin Mustafa KiyaniShifa College of Medical Technology, Shifa Tameer-e-Millat University, Islamabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder. It is the most prevalent disease in reproductive-aged females worldwide. PCOS is characterized by hormonal imbalance, chronic anovulation, and metabolic dysfunction. The complex etiology of PCOS, which involves genetic, environmental, and lifestyle factors, contributes to the variability in its clinical presentation and complicates treatment strategies. Current therapeutic and disease management options, including hormonal therapy, and insulin sensitizers are limited by the side effects associated with non-targeted approach. In recent years, nanomedicine has emerged as a promising approach to overcome these challenges. It offers enhanced bioavailability, targeted drug delivery, and reduced systemic toxicity. Nanoparticles (NPs) possess unique physicochemical properties including high drug loading capacity and a large surface area. They can bind both hydrophilic and hydrophobic substances. These characteristics make NPs a promising platform for targeted and controlled drug delivery. Challenges such as off-target effects and limited efficacy in traditional therapy are mitigated when therapeutic agents are combined with nanoparticles, increasing precision and therapeutic outcomes. This review provides a comprehensive summary of the unique properties of nanoparticles that play crucial roles in their interactions with reproductive systems. Further we focus on the mechanistic insights into how nanoparticles modulate key PCOS-related pathways, including insulin signaling, steroidogenesis, inflammation and oxidative stress. This review highlights the role of some specific nanocarriers (e.g.; curcumin loaded NPs, selenium NPs, and exosomes) in restoring metabolic and reproductive functions in PCOS. In addition, we discuss NPs synthesis, delivery mechanisms, and their interactions at the molecular and cellular levels to PCOS pathology, with their putative role in pathway linked modulation of insulin resistance, hyperandrogenism, inflammation, and disrupted folliculogenesis. Understanding these mechanisms is essential for designing effective, nanomedicine for PCOS and possibly for other PCOS related chronic diseases.

Indexed as

NanomedicineNanoparticlesPolycystic Ovary SyndromeAnimalsDrug Delivery SystemsFemaleHumansOxidative StressExosomesGreen synthesisInflammationInsulin resistancemicroRNANanomedicinePI3K/Akt/mTORPolycystic ovary syndrome(PTEN)-dependent signaling pathwaysTargeted drug delivery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.